IMMUNOPATHOGENESIS AND TREATMENT OF AUTOIMMUNE DISEASES: Edited by Cee s GM KallenbergInhibition of high-mobility group box 1 as therapeutic option in autoimmune disease lessons from animal modelsSchaper, Fleura; Heeringa, Peterb; Bijl, Marcc; Westra, Johannaa Author Information aDepartment of Rheumatology and Clinical Immunology bDepartment of Pathology and Medical Biology, Medical Biology Section, University Medical Center Groningen, University of Groningen cDepartment of Internal Medicine and Rheumatology, Martini Hospital, Groningen, The Netherlands Correspondence to Fleur Schaper, MSc, Department of Rheumatology and Clinical Immunology, AA21, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands. Tel: +31 50 361 2945; e-mail: [email protected] Current Opinion in Rheumatology 25(2):p 254-259, March 2013. | DOI: 10.1097/BOR.0b013e32835cee2d Buy Metrics Abstract Purpose of review High-mobility group box 1 (HMGB1) is a molecule that has gained much attention in the last couple of years as an important player in innate immune responses and modulating factor in several (auto)immune diseases. Furthermore, advancements have been made in identifying the diverse functions that HMGB1 can play in the body by studying its receptors, pathways and effects. This review will focus on the modulation of HMGB1 in animal models of (auto)immune diseases. Recent findings In different disease models like sepsis, ischemia–reperfusion and arthritis, HMGB1-blocking therapies have been tested and the disease course was shown to be ameliorated. Summary These findings indicate that HMGB1 is an important mediator in innate immunity, inflammation and sterile injury. Furthermore, HMGB1 might be a new therapeutic target in inflammation and autoimmune diseases, which may be translated to the clinic. © 2013 Lippincott Williams & Wilkins, Inc.